Cargando…

Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage

Farnesoid X receptor (FXR) activation has been reported to reduce inflammation and oxidative stress. Because both inflammation and oxidative stress are critical for tissue destruction during kidney ischemia reperfusion (I/R) injury, we investigated the protective role of FXR against kidney damage in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gai, Zhibo, Chu, Lei, Xu, Zhenqiang, Song, Xiaoming, Sun, Dongfeng, Kullak-Ublick, Gerd A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575310/ https://www.ncbi.nlm.nih.gov/pubmed/28852062 http://dx.doi.org/10.1038/s41598-017-10168-6

Ejemplares similares

The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
por: Rausch, Magdalena, et al.
Publicado: (2022)

Effects of Farnesiferol B on Ischemia-Reperfusion-Induced Renal Damage, Inflammation, and NF-κB Signaling
por: Zhang, Lu, et al.
Publicado: (2019)

Renal Glycosuria as a Novel Early Sign of Colistin-Induced Kidney Damage in Mice
por: Samodelov, Sophia L., et al.
Publicado: (2019)

The Role of Mitochondria in Drug-Induced Kidney Injury
por: Gai, Zhibo, et al.
Publicado: (2020)

Lipid Accumulation and Chronic Kidney Disease
por: Gai, Zhibo, et al.
Publicado: (2019)

Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats
por: Ceulemans, Laurens J., et al.
Publicado: (2017)

Antibiotic pretreatment attenuates liver ischemia–reperfusion injury by Farnesoid X receptor activation
por: Liu, Hanyi, et al.
Publicado: (2022)

Molecular Mechanisms of Colistin-Induced Nephrotoxicity
por: Gai, Zhibo, et al.
Publicado: (2019)

Organic Cation Transporters in Human Physiology, Pharmacology, and Toxicology
por: Samodelov, Sophia L., et al.
Publicado: (2020)

Renal Reabsorption of Folates: Pharmacological and Toxicological Snapshots
por: Samodelov, Sophia L, et al.
Publicado: (2019)

The Role of NF-kB in the Downregulation of Organic Cation Transporter 2 Expression and Renal Cation Secretion in Kidney Disease
por: Han, Chao, et al.
Publicado: (2022)

Farnesoid X Receptor Activation Protects Liver From Ischemia/Reperfusion Injury by Up‐Regulating Small Heterodimer Partner in Kupffer Cells
por: Jin, Dan, et al.
Publicado: (2020)

The Role of the Carnitine/Organic Cation Transporter Novel 2 in the Clinical Outcome of Patients With Locally Advanced Esophageal Carcinoma Treated With Oxaliplatin
por: Sun, Dongfeng, et al.
Publicado: (2021)

The organic solute transporters alpha and beta are induced by hypoxia in human hepatocytes
por: Schaffner, Carlos A, et al.
Publicado: (2015)

Astragaloside IV alleviates 1-deoxysphinganine-induced mitochondrial dysfunction during the progression of chronic kidney disease through p62-Nrf2 antioxidant pathway
por: Gui, Ting, et al.
Publicado: (2023)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

Cholesterol stimulates the cellular uptake of L-carnitine by the carnitine/organic cation transporter novel 2 (OCTN2)
por: Zhang, Lu, et al.
Publicado: (2021)

Plasma Sphingoid Base Profiles of Patients Diagnosed with Intrinsic or Idiosyncratic Drug-induced Liver Injury
por: Gai, Zhibo, et al.
Publicado: (2023)

The farnesoid X receptor agonist obeticholic acid upregulates biliary excretion of asymmetric dimethylarginine via MATE-1 during hepatic ischemia/reperfusion injury
por: Ferrigno, Andrea, et al.
Publicado: (2018)

Farnesoid X receptor promotes renal ischaemia‐reperfusion injury by inducing tubular epithelial cell apoptosis
por: Xu, Yao, et al.
Publicado: (2021)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

Current Concepts of Mechanisms in Drug-Induced Hepatotoxicity
por: Russmann, Stefan, et al.
Publicado: (2009)

Drug-induced liver injury: the dawn of biomarkers?
por: Weiler, Stefan, et al.
Publicado: (2015)

Farnesoid X receptor protects against cisplatin-induced acute kidney injury by regulating the transcription of ferroptosis-related genes
por: Kim, Dong-Hyun, et al.
Publicado: (2022)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

The effect of hypericum perforatum on kidney ischemia/reperfusion damage
por: Cakir, Murat, et al.
Publicado: (2017)

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor
por: She, Jianglian, et al.
Publicado: (2022)

The effect of Farnesoid X receptor agonist tropifexor on liver damage in rats with experimental obstructive jaundice
por: Kilavuz, Huseyin, et al.
Publicado: (2021)

Farnesoid X receptor activation inhibits TGFBR1/TAK1-mediated vascular inflammation and calcification via miR-135a-5p
por: Li, Chao, et al.
Publicado: (2020)

The role of the farnesoid X receptor in kidney health and disease: a potential therapeutic target in kidney diseases
por: Kim, Dong-Hyun, et al.
Publicado: (2023)

Irisin Is Controlled by Farnesoid X Receptor and Regulates Cholesterol Homeostasis
por: Li, Hong, et al.
Publicado: (2019)

Molecular tuning of farnesoid X receptor partial agonism
por: Merk, Daniel, et al.
Publicado: (2019)

Microbiota-induced obesity requires farnesoid X receptor
por: Parséus, Ava, et al.
Publicado: (2017)

Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases
por: Wu, Jin-nan, et al.
Publicado: (2020)

Farnesoid X Receptor (FXR) Aggravates Amyloid-β-Triggered Apoptosis by Modulating the cAMP-Response Element-Binding Protein (CREB)/Brain-Derived Neurotrophic Factor (BDNF) Pathway In Vitro
por: Chen, Qingfa, et al.
Publicado: (2019)

Author Correction: Farnesoid X receptor activation inhibits TGFBR1/TAK1-mediated vascular inflammation and calcification via miR-135a-5p
por: Li, Chao, et al.
Publicado: (2020)

Bacterial metabolites directly modulate farnesoid X receptor activity
por: Zhang, Xianqin, et al.
Publicado: (2015)

Allosteric modulation of the farnesoid X receptor by a small molecule
por: Gabler, Matthias, et al.
Publicado: (2018)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mu30p1g7tg4p33o6agc9q1d97o